Researchers from the Washington University School of Medicine in St. Louis have developed a blood test that can identify which patients with COVID-19 are at risk of severe disease or death and measures mitochondrial DNA present in the blood.
A Series A financing round has raised $100 million for Delfi Diagnostics. The funds will be used to expand its team of machine learning experts and cancer researchers as well as to validate its next-generation blood-based cancer test.
The Biomedical Advanced Research and Development Authority has given DiaSorin Molecular additional funding to validate its Simplexa COVID-19 & Flu A/B Direct kit and its Simplexa COVID-19 Direct kit. The funds will also be used for studied needed to obtain 510(k) clearance from the FDA.